Sarepta Therapeutics has appointed Michael Severino, M.D., as its new chief executive officer, effective July 28, 2026. Severino, who previously served as CEO of Tessera Therapeutics and held senior roles at AbbVie and Amgen, will also join Sarepta's Board of Directors. He succeeds Doug Ingram, who is retiring and will remain in an advisory capacity until the end of 2026. The company highlighted Severino's more than 25 years of biopharmaceutical experience and his track record of contributing to over a dozen approved therapies.
Sarepta Therapeutics IncAppointment of new CEO with extensive experience and track record is a leadership change that can drive future value.
AbbVie Inc
Amgen Inc